Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
Top Cited Papers
- 9 July 2003
- journal article
- clinical trial
- Published by Elsevier in Oral Oncology
- Vol. 39 (7) , 724-727
- https://doi.org/10.1016/s1368-8375(03)00097-6
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignanciesCancer, 2001
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- c-erbB-2/neu Oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasmsOtolaryngology -- Head and Neck Surgery, 1995
- HER-2/neu expression: A major prognostic factor in endometrial cancerGynecologic Oncology, 1992
- c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodesBritish Journal of Cancer, 1991
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Malignant salivary tumors—analysis of prognostic factors and survivalHead & Neck Surgery, 1986
- Salivary neoplasms: Overview of a 35‐year experience with 2,807 patientsHead & Neck Surgery, 1986
- Cyclophosphamide, adriamycin, and cisdiamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancerCancer, 1983